Sunday, January 18, 2026
spot_imgspot_imgspot_img

Oncology Molecular Diagnostics Market to Reach USD 3.68 billion with 2031, Driven by Rising Importance of Precise Genomic Information in Treatment Planning


Mordor Intelligence has published a new report on Oncology Molecular Diagnostics Market, offering a comprehensive analysis of trends, growth drivers, and future projections. 

Introduction:  

Oncology Molecular Diagnostics Market size in 2026 is estimated at USD 4.13 billion, growing from 2025 value of USD 3.68 billion with 2031 projections showing USD 7.33 billion, growing at 12.18% CAGR over 2026-2031, reflecting robust demand and steady oncology molecular diagnostics market growth. This growth is driven by increasing cancer incidence worldwide and the rising importance of precise genomic information in treatment planning. Patients, clinicians, and healthcare systems are placing greater emphasis on tests that help determine targeted treatment options, monitor disease progression, or detect minimal residual disease. As a result, the oncology molecular diagnostics market is gaining broader adoption across hospitals, reference laboratories, and decentralized care settings worldwide.  

Key Trends 

The oncology molecular diagnostics marketanalysis indicates several noteworthy trends influencing how clinicians and laboratories adopt and utilize testing solutions: 

  1. Liquid Biopsy Adoption and Companion Diagnostics

Non-invasive liquid biopsies continue to gain traction as alternatives or complements to traditional tissue biopsies, enabling repeated sampling for genomic monitoring without additional invasive procedures. Regulatory approvals of companion diagnostics tied to targeted therapies have supported broader clinical uptake.  

  1. Integration of AI and Bioinformatics

Artificial intelligence and bioinformatics platforms are becoming more prevalent, helping laboratories interpret complex genomic data faster and with greater accuracy. These tools can automate variant calling and reduce turnaround times, boosting the appeal of comprehensive molecular profiling.  

  1. Shift Toward Decentralized Testing

Point-of-care platforms and simplified molecular assays are enabling oncology testing beyond traditional central laboratories. Cartridge-based systems and ease-of-use features allow smaller clinics and community hospitals to provide molecular diagnostic insights more rapidly.  

  1. Regional Growth Dynamics

Geographically, North America remains the largest contributor to the oncology molecular diagnostics market due to established healthcare infrastructure and reimbursement frameworks, while the Asia-Pacific region shows the fastest oncology molecular diagnostics marketgrowth as national genomics programs expand and cancer testing demand increases.  

Market Segmentation  

The oncology molecular diagnostics market is structured around several essential segments, capturing product types, technologies, sample categories, end users, and geographies. This segmentation helps stakeholders understand where demand is strongest and how adoption patterns vary across clinical and regional contexts. 

By Product Type 

  • Instruments 
  • Reagents & Consumables 
  • Software & Services 

By Technology 

  • Polymerase Chain Reaction (PCR) 
  • Isothermal NAAT 
  • Next-Generation Sequencing (NGS) 
  • In-situ Hybridization (FISH/CISH) 
  • Mass Spectrometry 
  • Chips & Microarrays 
  • Transcription-Mediated Amplification 

By Cancer Type 

  • Breast Cancer 
  • Lung Cancer 
  • Colorectal Cancer 
  • Prostate Cancer 
  • Hematological Malignancies 
  • Liver Cancer 
  • Cervical & Gynecologic Cancers 
  • Other Solid Tumors 

By Sample Type 

  • Tissue Biopsy 
  • Liquid Biopsy (Blood/Plasma/Serum) 
  • Fine-Needle Aspirates & Cytology Samples 

By End User 

  • Hospitals 
  • Diagnostic Centers 
  • Point-of-Care Settings 

By Geography 

  • North America 
  • South Amerca 
  • Middle east&Africa 
  • Europe 
  • Asia pacific 

Key Players  

The competitive landscape of the oncology molecular diagnostics market showcases several established and emerging industry participants actively shaping the sector: 

  • Illumina Inc. 
  • Qiagen N.V. 
  • F. Hoffmann-La Roche Ltd 
  • Thermo Fisher Scientific Inc. 
  • Danaher Corporation 

These key players leverage strategic collaborations, product enhancements, and expanded service offerings to maintain and grow their positions within the global oncology molecular diagnostics landscape. The emphasis on partnerships and incremental improvements reflects an oncology molecular diagnostics marketShare driven by both innovation and clinical demand.  

Conclusion: 

The oncology molecular diagnostics market continues to grow steadily as clinicians, laboratories, and health systems prioritize precision cancer care. With an estimated forecasted value approaching USD 6.58 billion by 2030, the market’s trajectory reflects broader shifts toward personalized medicine, real-time disease monitoring, and decentralized testing capabilities. Emerging oncology molecular diagnostics markettrends such as liquid biopsy adoption, AI integration, and geographic expansion into high-growth regions indicate that stakeholders have multiple avenues to support improved diagnostic outcomes. 

Industry related Reports: 

Clinical Diagnostics Market : The Clinical Diagnostics Market Report is Segmented by Test (Lipid Panel, and More), Product (Instruments, Reagents, and More), Technology (Clinical Chemistry, and More), Sample Type (Urine, and More), Setting (Centralized Clinical Laboratories, and More), End User (Hospital Laboratories, Point-Of-Care Settings, and More), and Geography (North America, Europe, and More). 

Cancer Profiling Market : The Cancer Profiling Market Report Segments the Industry Into by Product and Services (Instruments, Consumables, Other Product and Services), by Technology (Immunoassays, Next Generation Sequencing, Other Technologies), by Cancer Type (Breast Cancer, Lung Cancer, Other Cancer Types), by Biomarker Type (Genetic Biomarkers, Protein Biomarkers, Other Biomarker Types), and Geography (North America, Europe, Asia-Pacific, and More). 

Cancer Biopsy Market: The Cancer Biopsy Market Report is Segmented by Product (Instruments, Kits and Consumables, and More), Procedure (Tissue Biopsy [Core Needle, and More], and Liquid Biopsy [Blood, Urine and More]), Cancer Type (Breast, Colorectal, Cervical, Lung, and More), End User (Hospitals, Diagnostic Laboratories, and More), and Geography (North America, Europe, Asia-Pacific, and More). 

About Mordor Intelligence: 

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals. 

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics. 

For any inquiries or to access the full report, please contact: 

media@mordorintelligence.com
https://www.mordorintelligence.com/ 



Source link

spot_imgspot_imgspot_img

Related News

spot_imgspot_imgspot_img

Share Us

Latest News